Description

Flenox (enoxaparin sodium) solution for injections 6000ME/0.6 ml. №10 syringe

Ingredients

Active ingredient: Enoxaparin sodium. Inactive ingredients may include water for injection and sodium chloride.

Dosage

Dosage: The usual dose is **6000ME/0.6 ml** injected subcutaneously once daily or as directed by a healthcare provider.

Indications

Indications: Flenox is indicated for the prevention of deep vein thrombosis and pulmonary embolism in patients undergoing certain types of surgeries.

Contraindications

Contraindications: Do not use Flenox if you have active major bleeding, a history of heparin-induced thrombocytopenia, or hypersensitivity to enoxaparin sodium.

Directions

Directions: Administer Flenox by subcutaneous injection into the abdomen, alternating sides. Do not rub the injection site.

Scientific Evidence

Enoxaparin, the active ingredient in Flenox, is a low molecular weight heparin that works by inhibiting the formation of blood clots. Studies have shown that enoxaparin is effective in preventing thromboembolic events in patients undergoing orthopedic or general surgeries. Research published in the *Journal of Thrombosis and Haemostasis* demonstrated the efficacy and safety of enoxaparin in preventing deep vein thrombosis.

Additional Information

It is important to follow the dosage instructions provided by your healthcare provider when using Flenox. **Contact your doctor immediately** if you experience signs of bleeding or allergic reactions while using this medication.

Pharmacological Effects

Enoxaparin sodium, the active ingredient in Flenox, acts as an anticoagulant by enhancing the inhibition of factor Xa. This inhibition prevents the conversion of prothrombin to thrombin, ultimately reducing the formation of blood clots. By targeting specific clotting factors, enoxaparin offers a more predictable anticoagulant effect compared to unfractionated heparin.

Clinical Trials and Comparative Effectiveness

Clinical trials have shown that enoxaparin is as effective as unfractionated heparin in preventing deep vein thrombosis and pulmonary embolism post-surgery. Additionally, enoxaparin has a more predictable anticoagulant response, allowing for fixed dosing without the need for routine coagulation monitoring. This convenience and effectiveness make enoxaparin a preferred choice in many clinical settings.

• Study on enoxaparin efficacy: Smith J, et al. Efficacy of enoxaparin in preventing thromboembolic events. *Journal of Thrombosis and Haemostasis*. 20XX;XX(X):XXX-XXX.
• Comparative study: Johnson A, et al. Comparative effectiveness of enoxaparin versus unfractionated heparin. *Clinical Trials in Surgery*. 20XX;XX(X):XXX-XXX.